What is mycophenolate mofetil classified as?
What is mycophenolate mofetil classified as?
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).
Is mycophenolate mofetil used to treat cancer?
Drugs used in chemotherapy, such as cyclophosphamide, tacrolimus, and mycophenolate mofetil, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
What is mycophenolate mofetil made from?
Mycophenolate can be derived from the fungi Penicillium stoloniferum, P. brevicompactum and P. echinulatum. Mycophenolate mofetil is metabolised in the liver to the active moiety mycophenolic acid.
What are the side effects of mycophenolate?
Commonly reported side effects of mycophenolate mofetil include: asthma, herpes simplex infection, infection, metabolic acidosis, oral candidiasis, pleural effusion, respiratory tract infection, systemic cytomegalovirus disease, urinary tract infection, viremia, abdominal pain, acne vulgaris, anemia, anxiety, asthenia.
Is mycophenolate safe long term?
Conclusions: Mycophenolate mofetil is safe for long-term usage and is recommended for treatment of refractory panuveitis or posterior uveitis with uncontrolled inflammation despite high prednisolone maintenance dosage (>15 mg/day) or toxicity or lack of efficacy of other immuno-suppressive agents.
What is the best time to take mycophenolate?
It is usually taken twice a day on an empty stomach (1 hour before or 2 hours after eating or drinking, unless your doctor tells you otherwise). Take mycophenolate at about the same times every day, and try to space your doses about 12 hours apart.
Does mycophenolate mofetil cause weight gain?
Weight gain wasn’t a side effect reported in clinical studies of CellCept. However, swelling in the ankles, feet, or legs can occur with this drug.
Is mycophenolate mofetil a steroid?
Mycophenolate mofetil (MMF), in particular, is a promising agent that should be strongly considered as a first-line steroid-sparing agent.